[Clinical Development of Immune Checkpoint Inhibitors in Patients with Small Cell Lung Cancer].

Small cell lung cancer (SCLC) is a poorly differentiated high-grade neuroendocrine tumor, accounts for approximately 14% of all lung cancers. SCLC is characterized by rapid growth, early metastasis without effective treatments after recurrence. It is urgently need to improve the therapy of patients with SCLC. In recent years Tumor immunotherapy has shown promising efficacy, especially in immune checkpoints including inhibitors programmed cell-death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). These immune checkpoint inhibitors of the researches are changing the clinical practice of many kinds of solid tumor. SCLC is a potential ideal type of tumor immunotherapy for tobacco exposure and the highest mutational load. In this report, the authors review the current state of the immunotherapy in SCLC, to discussing the problems, challenge and application development prospect.